132 related articles for article (PubMed ID: 24873798)
1. Improvement in diagnosis of metastatic pituitary carcinoma by 68Ga DOTATATE PET/CT.
Xiao J; Zhu Z; Zhong D; Ma W; Wang R
Clin Nucl Med; 2015 Feb; 40(2):e129-31. PubMed ID: 24873798
[TBL] [Abstract][Full Text] [Related]
2. The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma.
Novruzov F; Aliyev JA; Jaunmuktane Z; Bomanji JB; Kayani I
Clin Nucl Med; 2015 Jan; 40(1):47-9. PubMed ID: 25275413
[TBL] [Abstract][Full Text] [Related]
3. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study.
Wang H; Hou B; Lu L; Feng M; Zang J; Yao S; Feng F; Wang R; Li F; Zhu Z
J Nucl Med; 2018 Mar; 59(3):523-528. PubMed ID: 28775202
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI.
Janssen I; Chen CC; Taieb D; Patronas NJ; Millo CM; Adams KT; Nambuba J; Herscovitch P; Sadowski SM; Fojo AT; Buchmann I; Kebebew E; Pacak K
J Nucl Med; 2016 Feb; 57(2):186-91. PubMed ID: 26564322
[TBL] [Abstract][Full Text] [Related]
5. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
7. 68Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma.
Basu S; Ranade R; Hazarika S
Clin Nucl Med; 2016 Mar; 41(3):230-1. PubMed ID: 26462040
[TBL] [Abstract][Full Text] [Related]
8. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia.
Agrawal K; Bhadada S; Mittal BR; Shukla J; Sood A; Bhattacharya A; Bhansali A
Clin Nucl Med; 2015 Jan; 40(1):e6-e10. PubMed ID: 24999675
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer.
Walker R; Deppen S; Smith G; Shi C; Lehman J; Clanton J; Moore B; Burns R; Grogan EL; Massion PP
PLoS One; 2017; 12(2):e0171301. PubMed ID: 28182730
[TBL] [Abstract][Full Text] [Related]
12. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTATATE PET/CT in Pituitary Carcinoma.
Kaya G; Soydas Turan B; Dagdelen S; Berker M; Tuncel M
Clin Nucl Med; 2021 Dec; 46(12):996-998. PubMed ID: 34269734
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
15. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
18. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTATATE uptake in pineal gland, a rare physiological variant: case series.
Riaz S; Syed R; Skoura E; Alshammari A; Gaze M; Sajjan R; Halsey R; Bomanji J
Ann Nucl Med; 2015 Nov; 29(9):833-7. PubMed ID: 26173444
[TBL] [Abstract][Full Text] [Related]
20. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
